JP7254515B2 - 抗ｄｒ５抗体およびその使用方法 - Google Patents

抗ｄｒ５抗体およびその使用方法 Download PDF

Info

Publication number
JP7254515B2
JP7254515B2 JP2018529087A JP2018529087A JP7254515B2 JP 7254515 B2 JP7254515 B2 JP 7254515B2 JP 2018529087 A JP2018529087 A JP 2018529087A JP 2018529087 A JP2018529087 A JP 2018529087A JP 7254515 B2 JP7254515 B2 JP 7254515B2
Authority
JP
Japan
Prior art keywords
antibody
seq
region
mutations
igg1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018529087A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019500869A (ja
JP2019500869A5 (OSRAM
Inventor
マリジュ オーバーダイク
クリスティン ストルマン
リック ラドメーカー
エステル ブレイジュ
ジェニン シュールマン
ポール パレン
Original Assignee
ジェンマブ ビー．ブイ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェンマブ ビー．ブイ． filed Critical ジェンマブ ビー．ブイ．
Publication of JP2019500869A publication Critical patent/JP2019500869A/ja
Publication of JP2019500869A5 publication Critical patent/JP2019500869A5/ja
Application granted granted Critical
Publication of JP7254515B2 publication Critical patent/JP7254515B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2018529087A 2015-12-01 2016-12-01 抗ｄｒ５抗体およびその使用方法 Active JP7254515B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
DKPA201500771 2015-12-01
DKPA201500771 2015-12-01
DKPA201500788 2015-12-07
DKPA201500788 2015-12-07
DKPA201500787 2015-12-07
DKPA201500787 2015-12-07
DKPA201600701 2016-11-10
DKPA201600702 2016-11-10
DKPA201600701 2016-11-10
DKPA201600702 2016-11-10
PCT/EP2016/079518 WO2017093448A1 (en) 2015-12-01 2016-12-01 Anti-dr5 antibodies and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2019500869A JP2019500869A (ja) 2019-01-17
JP2019500869A5 JP2019500869A5 (OSRAM) 2020-01-16
JP7254515B2 true JP7254515B2 (ja) 2023-04-10

Family

ID=58796495

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018529176A Withdrawn JP2019501151A (ja) 2015-12-01 2016-12-01 抗デスレセプター抗体およびその使用方法
JP2018529087A Active JP7254515B2 (ja) 2015-12-01 2016-12-01 抗ｄｒ５抗体およびその使用方法
JP2022188988A Active JP7679347B2 (ja) 2015-12-01 2022-11-28 抗デスレセプター抗体およびその使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018529176A Withdrawn JP2019501151A (ja) 2015-12-01 2016-12-01 抗デスレセプター抗体およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022188988A Active JP7679347B2 (ja) 2015-12-01 2022-11-28 抗デスレセプター抗体およびその使用方法

Country Status (15)

Country Link
US (5) US20190144554A1 (OSRAM)
EP (4) EP3383906A1 (OSRAM)
JP (3) JP2019501151A (OSRAM)
KR (1) KR20180098567A (OSRAM)
CN (2) CN109476737A (OSRAM)
AU (2) AU2016363770A1 (OSRAM)
BR (2) BR112018011100A2 (OSRAM)
CA (2) CA3007031A1 (OSRAM)
IL (1) IL259713B1 (OSRAM)
MA (1) MA43365A (OSRAM)
MX (1) MX2018006333A (OSRAM)
SG (1) SG11201803956UA (OSRAM)
UA (1) UA126897C2 (OSRAM)
WO (2) WO2017093447A1 (OSRAM)
ZA (1) ZA201803079B (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3960855A1 (en) * 2001-12-28 2022-03-02 Chugai Seiyaku Kabushiki Kaisha Method for stabilizing proteins
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
CA3007031A1 (en) 2015-12-01 2017-06-08 Genmab B.V. Anti-death receptor antibodies and methods of use thereof
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CA3033665A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
EP3635005A1 (en) * 2017-06-07 2020-04-15 Genmab B.V. Therapeutic antibodies based on mutated igg hexamers
MA50102A (fr) * 2017-11-14 2020-07-15 Univ Virginia Patent Foundation Compositions et méthodes de fabrication et d'utilisation d'anticorps bispécifiques
CN109957020A (zh) * 2017-12-25 2019-07-02 深圳宾德生物技术有限公司 一种靶向dr5的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
US20210107988A1 (en) * 2018-01-24 2021-04-15 Genmab B.V. Polypeptide variants and uses thereof
BR112020022179A2 (pt) 2018-05-03 2021-02-02 Genmab B.V. primeiro anticorpo, anticorpo, composição, métodos para tratar um indivíduo tendo uma doença, para esgotar uma população de célula e para induzir a proliferação em uma população de célula, e, kit.
MA53122A (fr) * 2018-07-13 2021-05-19 Genmab As Variants d'anticorps cd38 et leurs utilisations
EP3837283B1 (en) * 2018-08-16 2024-04-17 Cantargia AB Anti-il1rap antibody compositions
WO2020225456A1 (en) 2019-05-09 2020-11-12 Genmab B.V. Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer
EP4055046A1 (en) 2019-11-06 2022-09-14 Genmab B.V. Antibody variant combinations and uses thereof
KR20230010221A (ko) * 2020-05-12 2023-01-18 아이쥐엠 바이오사이언스 인코포레이티드 암 치료를 위한 암 요법과 병용된 다량체 항-dr5 결합 분자의 용도
CN111778333B (zh) * 2020-07-03 2022-11-18 东莞市滨海湾中心医院 测定edar表达水平的试剂的应用和试剂盒
WO2022018294A1 (en) 2020-07-23 2022-01-27 Genmab B.V. A combination of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
WO2022081869A1 (en) * 2020-10-14 2022-04-21 University Of Virginia Patent Foundation Compositions and methods for overcoming dr5-induced immune evasion by solid tumors
CN112915211B (zh) * 2021-02-07 2022-05-06 成都中医药大学 一种pd-l1靶向肽药物偶联物及其合成方法和应用
EP4388013A4 (en) * 2021-08-20 2025-12-24 Univ Virginia Patent Foundation A HIGHLY SUPERIOR DR5 ACTIVATION STRATEGY, PARTICULARLY IN TUMORS AND CANCERS
TW202509071A (zh) * 2023-05-12 2025-03-01 丹麥商珍美寶股份有限公司 能夠與ｏｘ４０結合之抗體、其變異體及其用途
GB202315963D0 (en) * 2023-10-18 2023-11-29 Cancer Research Tech Ltd Binding molecules
WO2025160152A2 (en) * 2024-01-23 2025-07-31 The Regents Of The University Of California Fas antibody and its use in treating cancers

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009505676A (ja) 2005-08-31 2009-02-12 アムジエン・インコーポレーテツド Ｔｒａｉｌ受容体２ポリペプチダーゼ及び抗体
JP2013541947A (ja) 2010-09-22 2013-11-21 アムジエン・インコーポレーテツド 担体としての免疫グロブリンおよびその使用
WO2014108198A1 (en) 2013-01-10 2014-07-17 Genmab B.V. Human igg1 fc region variants and uses thereof
JP2014520788A (ja) 2011-07-06 2014-08-25 ゲンマブ ビー．ブイ． 抗体変異体およびその使用
CN104619725A (zh) 2012-07-09 2015-05-13 国际生物技术药物开发公司 抗-dr5家族抗体,双特异性或多价抗-dr5家族抗体及其应用方法

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077A (en) 1849-01-30 Improved hinged claw-wrench
US835A (en) 1838-07-12 X i i i x
US761218A (en) 1899-10-05 1904-05-31 U S Standard Voting Machine Co Register or counter.
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6284236B1 (en) 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
CA2249206A1 (en) 1996-04-01 1997-10-09 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides
ES2284199T5 (es) 1997-01-28 2011-11-14 Human Genome Sciences, Inc. Receptor 4 que contiene dominio de muerte (dr4: receptor 4 de muerte), miembro de la superfamilia de receptores de tnf y unión a trail (apo-2l).
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US20050233958A1 (en) 1997-03-17 2005-10-20 Human Genome Sciences, Inc. Death domain containing receptor 5
AU751659B2 (en) 1997-05-02 2002-08-22 Genentech Inc. A method for making multispecific antibodies having heteromultimeric and common components
ES2316182T3 (es) 1998-01-15 2009-04-01 Genentech, Inc. Ligando apo-2.
CA2329940A1 (en) 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
US6355271B1 (en) 1999-02-03 2002-03-12 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
WO2000075191A2 (en) 1999-06-09 2000-12-14 Genentech, Inc. Apo-2L RECEPTOR AGONIST AND CPT-11 SYNERGISM
US6444640B1 (en) 1999-09-30 2002-09-03 Ludwig Institute For Cancer Research Compositions of trail and DNA damaging drugs and uses thereof
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
US20020155109A1 (en) 2001-04-20 2002-10-24 Lynch David H. Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2
US7115717B2 (en) 2001-05-18 2006-10-03 Kirin Beer Kabushiki Kaisha Anti-TRAIL-R antibodies
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
ES2437992T3 (es) * 2001-05-25 2014-01-15 Human Genome Sciences, Inc. Anticuerpos que se unen inmunoespecíficamente a los receptores de TRAIL
CA2451680C (en) 2001-07-03 2011-04-19 Genentech, Inc. Human dr4 antibodies and uses thereof
IL161686A0 (en) 2001-11-01 2004-09-27 Uab Research Foundation Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
US20040019915A1 (en) 2002-04-01 2004-01-29 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 213P1F11 useful in treatment and detection of cancer
KR100932340B1 (ko) 2002-10-17 2009-12-16 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
US20050266008A1 (en) 2004-03-29 2005-12-01 Medarex, Inc. Human anti-IRTA-5 antibodies
KR20070010046A (ko) 2004-04-06 2007-01-19 제넨테크, 인크. Ｄｒ5 항체 및 그의 용도
CN101001873B (zh) * 2004-08-04 2013-03-13 曼璀克生物科技有限责任公司 Fc区变体
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
EP3332808B1 (en) 2005-03-03 2020-09-09 Immunomedics Inc. Humanized l243 antibodies
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
AU2007227292B2 (en) 2006-03-17 2012-04-12 Biogen Ma Inc. Stabilized polypeptide compositions
CA2646965C (en) 2006-03-24 2016-06-21 Jonathan H. Davis Engineered heterodimeric protein domains
KR100847010B1 (ko) 2006-07-05 2008-07-17 아주대학교산학협력단 세포사멸 수용체 5 (ｄｒ5)에 특이적으로 결합하는 항체 및이를 포함하는 암 예방 또는 치료용 조성물
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
KR101799337B1 (ko) 2007-06-21 2017-12-20 마크로제닉스, 인크. 공유결합형 디아바디 및 이것의 사용
TW200904072A (en) 2007-07-05 2009-01-16 Ic Plus Corp System and method for generating interrupt
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
EP2540740B1 (en) 2008-06-17 2014-09-10 Apogenix GmbH Multimeric TNF receptors
EP2166021A1 (en) * 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
SG10201407908VA (en) 2008-12-19 2015-01-29 Macrogenics Inc Covalent diabodies and uses thereof
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
US20120070432A1 (en) 2009-05-28 2012-03-22 Amgen Inc. Treatment of pancreatic cancer using a dr5 agonist in combination with gemcitabine
MX368932B (es) 2009-06-26 2019-10-22 Regeneron Pharma Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original.
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
JP5997154B2 (ja) 2010-08-16 2016-09-28 ノビミューン エスアー 多重特異性多価抗体の生成方法
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
RU2013110876A (ru) 2010-08-24 2014-09-27 Рош Гликарт Аг Активируемые биспецифические антитела
RU2644678C1 (ru) * 2010-10-29 2018-02-13 Дайити Санкио Компани, Лимитед Новое антитело против dr5
RU2604490C2 (ru) 2010-11-05 2016-12-10 Займворкс Инк. ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
CN102654260B (zh) 2011-09-29 2014-09-03 北京京东方光电科技有限公司 一种背光源和液晶显示器
PL2794905T3 (pl) 2011-12-20 2020-11-02 Medimmune, Llc Zmodyfikowane polipeptydy dla rusztowań przeciwciał dwuswoistych
CN120383672A (zh) 2012-04-20 2025-07-29 美勒斯公司 用于产生免疫球蛋白样分子的方法和手段
DK2869845T3 (da) 2012-07-06 2019-12-09 Genmab Bv Dimert protein med tredobbelte mutationer
JP6514103B2 (ja) 2012-07-06 2019-05-15 ゲンマブ ビー．ブイ． 三重変異を有する二量体タンパク質
EP3048116A1 (en) * 2015-01-23 2016-07-27 International-Drug-Development-Biotech Anti-dr5 antibodies with enhanced apoptosis potency
CA3007031A1 (en) 2015-12-01 2017-06-08 Genmab B.V. Anti-death receptor antibodies and methods of use thereof
EP3535291A1 (en) 2016-11-01 2019-09-11 Genmab B.V. Polypeptide variants and uses thereof
JP7577446B2 (ja) 2017-02-10 2024-11-05 ジェンマブ ビー．ブイ． ポリペプチドバリアントおよびそれらの使用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009505676A (ja) 2005-08-31 2009-02-12 アムジエン・インコーポレーテツド Ｔｒａｉｌ受容体２ポリペプチダーゼ及び抗体
JP2013541947A (ja) 2010-09-22 2013-11-21 アムジエン・インコーポレーテツド 担体としての免疫グロブリンおよびその使用
JP2014520788A (ja) 2011-07-06 2014-08-25 ゲンマブ ビー．ブイ． 抗体変異体およびその使用
CN104619725A (zh) 2012-07-09 2015-05-13 国际生物技术药物开发公司 抗-dr5家族抗体,双特异性或多价抗-dr5家族抗体及其应用方法
JP2015527992A (ja) 2012-07-09 2015-09-24 アンテルナショナル−ドラック−ディベロップメント−バイオテック 抗−ｄｒ５ファミリー抗体、二重特異性又は多価の抗−ｄｒ５ファミリー抗体及びそれらの使用方法
WO2014108198A1 (en) 2013-01-10 2014-07-17 Genmab B.V. Human igg1 fc region variants and uses thereof

Also Published As

Publication number Publication date
CA3007031A1 (en) 2017-06-08
US20210324096A1 (en) 2021-10-21
UA126897C2 (uk) 2023-02-22
CN109476737A (zh) 2019-03-15
EP3383906A1 (en) 2018-10-10
US12247080B2 (en) 2025-03-11
JP2019500869A (ja) 2019-01-17
AU2016363770A1 (en) 2018-06-28
AU2024200261A1 (en) 2024-02-01
EP4464333A3 (en) 2025-05-14
CN108884158A (zh) 2018-11-23
ZA201803079B (en) 2023-12-20
JP7679347B2 (ja) 2025-05-19
JP2023022186A (ja) 2023-02-14
SG11201803956UA (en) 2018-06-28
NZ743316A (en) 2023-12-22
EP4467648A3 (en) 2025-02-26
US20190202926A1 (en) 2019-07-04
MA43365A (fr) 2018-10-10
MX2018006333A (es) 2018-08-01
US20220411522A1 (en) 2022-12-29
EP3383905A1 (en) 2018-10-10
BR112018011058A2 (en) 2018-11-21
KR20180098567A (ko) 2018-09-04
US10882913B2 (en) 2021-01-05
IL259713A (en) 2018-07-31
US20190144554A1 (en) 2019-05-16
IL259713B1 (en) 2025-11-01
WO2017093447A1 (en) 2017-06-08
US20190315877A1 (en) 2019-10-17
EP4464333A2 (en) 2024-11-20
JP2019501151A (ja) 2019-01-17
WO2017093448A1 (en) 2017-06-08
EP4467648A2 (en) 2024-11-27
CA3007033A1 (en) 2017-06-08
BR112018011100A2 (en) 2018-12-04

Similar Documents

Publication Publication Date Title
JP7254515B2 (ja) 抗ｄｒ５抗体およびその使用方法
JP7701964B2 (ja) Ｃｄ１３７及びｏｘ４０に結合する抗体分子
KR102718932B1 (ko) 항-cd39 항체, 항-cd39 항체를 포함하는 조성물 및 항-cd39 항체를 사용하는 방법
JP2023145720A (ja) 変異ＩｇＧ六量体に基づく治療用抗体
WO2020225456A1 (en) Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer
HK40120020A (en) Anti-dr5 antibodies and methods of use thereof
HK40118860A (en) Anti-death receptor antibodies and methods of use thereof
JP2023534726A (ja) 多発性骨髄腫の治療に使用するための抗ｄｒ５抗体と免疫調節イミド薬との併用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201019

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201023

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210416

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210709

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220727

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230126

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230301

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230329

R150 Certificate of patent or registration of utility model

Ref document number: 7254515

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150